Abstract
Objectives: To determine the expression of carcinoma, 40% were grade III and 35% and 25%
HER2 in adenoid cystic and mucoepidermoid were grade I and III, respectively. Out of 20 cases,
carcinoma of salivary glands, if can be used as a 80% were grade I while 5% and 15% were grade II
prognostic marker as well as for therapeutic and grade III correspondingly in adenoid cystic
approach. carcinoma. Lymph node involvement was seen
Methodology: Forty cases of mucoepidermiod 45% of mucoepidermoid carcinoma while it was
carcinoma (n=20) and adenoid cystic carcinoma not present in adenoid cystic carcinoma.
(n=20) were taken from various hospitals of HER 2 immunopositivity was seen as brownish
Lahore. Relevant clinical data was recorded and membranous staining in 85% among 100 cases of
blocks were examined for histological diagnosis. both mucoepidermoid carcinoma adenoid cystic
HER2 immunopositivity was assessed by carcinoma. Statistically, significant association
immunohistochemistry. Tumors with (+2) to (+3) was found between HER2 expression and tumor
score were considered as positive for grade.
overexpression. Conclusion: Positive expression of HER2 in both
Results: Mean age was 32.35±13.674 and mucoepidermoid and adnoidcyctic carcinoma
41.50±12.224 while male to female ratio was 1.5:1 shows the development and progression of
and 1:1.5 in mucoepidermoid carcinoma and carcinoma. It could be used as a prognostic
adenoid cystic, respectively. Parotid gland was the marker and also for potential therapeutic
common site in mucoepidermoid carcinoma, while approach. (Rawal Med J 201;43:354-357).
minor salivary glands was the most affected site in Key words: Mucoepidrmoid carcinoma, adenoid
adenoid cystic carcinoma. Both carcinomas were cystic carcinoma, HER2.
